Published on in Vol 5, No 3 (2018): Jul-Sept

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/10070, first published .
Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Journals

  1. Ngai L, ter Veer E, van den Boorn H, van Herk E, van Kleef J, van Oijen M, van Laarhoven H. TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncologica 2019;58(8):1138 View
  2. Li L, Kong F, Zhang L, Li X, Fu X, Wang X, Wu J, Zhang F, Ren L, Zhang M. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs 2020;38(6):1847 View
  3. Lazarewicz M, Wlodarczyk D, Lundgren S, Reidunsdatter R. Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses. Quality of Life Research 2019;28(6):1521 View
  4. Cheng M, Lee H, Chang W, Lee N, Huang H, Chen Y, Horng H, Lee W, Wang P. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. International Journal of Environmental Research and Public Health 2019;16(23):4794 View
  5. Xiao Y, Zeng L, Shen Q, Zhou Z, Mao Z, Wang Q, Zhang X, Li Y, Yao W. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. Journal of Immunology Research 2020;2020:1 View
  6. Huang C, Cheng M, Lee N, Huang H, Lee W, Chang W, Wang P. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. International Journal of Environmental Research and Public Health 2020;17(7):2213 View
  7. Basch E, Stover A, Schrag D, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears P, Jonsson M, Bennett A, Mody G, Thanarajasingam G, Rogak L, Reeve B, Snyder C, Kottschade L, Charlot M, Weiss A, Bruner D, Dueck A. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. JCO Clinical Cancer Informatics 2020;(4):947 View
  8. Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magrì V, Palleschi M, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F. Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncology 2021 View
  9. Lee M, Kang D, Kim S, Lim J, Yoon J, Kim Y, Shim S, Kang E, Ahn J, Cho J, Shin S, Oh D. Who is more likely to adopt and comply with the electronic patient-reported outcome measure (ePROM) mobile application? A real-world study with cancer patients undergoing active treatment. Supportive Care in Cancer 2021 View